

#### **Patient Enrollment Form**

Fax completed forms to: 1 (855) 813-2039

## **Patient Enrollment Form**

Mito Assist™ is a patient and family support program available at no cost for eligible patients prescribed FORZINITY™ (elamipretide) injection for subcutaneous administration. Sponsored by Stealth BioTherapeutics Inc., the maker of FORZINITY, Mito Assist offers support services for qualified patients related to insurance coverage and access for FORZINITY, patient support programs, support for at-home subcutaneous injection training, and education and resources.

Accessing Mito Assist starts with a Patient Enrollment Form completed by the prescribing healthcare provider (HCP) and eligible patient/patient representative.

#### Getting started with Mito Assist:

- 1. Complete the Patient Enrollment Form in its entirety fill out all 5 pages
  - a. Sections 1-3 can be completed by the patient/patient representative or the HCP
  - b. Sections 4-8 should be filled out and signed by the HCP
    - i. Section 5 is the prescription (Rx) and should be filled out according to the label instructions on the FORZINITY package insert
    - ii. Section 6 includes medical criteria/clinical information that should be filled out by the HCP to confirm the patient's diagnosis
    - iii. Section 7 contains the prescriber authorization
    - iv. Section 8 is an optional order for nurse support
  - c. Section 9 should be read and signed by the patient/patient representative
- 2. The patient/patient representative must sign and date the Patient Consent and Authorization of the Patient Enrollment Form (Section 9) to be enrolled in Mito Assist
  - a. The patient/patient representative (or caregiver) signature is required to access Mito Assist support services (for example, patient and copay assistance), and other financial assistance programs
  - b. HCPs are strongly encouraged to have the patient/patient representative sign the consent form during the in-person visit when FORZINITY is prescribed to facilitate relevant support
- 3. Fax the completed Patient Enrollment Form to 1 (855) 813-2039, along with the following documents:
  - a. Copy of patient's primary and secondary (if applicable) insurance cards (front and back)
  - b. Supporting medical information to aid the prior authorization process
- 4. Let your patient know that you are submitting the Patient Enrollment Form and that they should expect a call from our exclusive specialty pharmacy partner, AnovoRx Group, LLC ("Anovo")



# **Patient Enrollment Form**

Please select one: Newly prescribed patient Patient currently on elamipretide

	Section 1: To be completed by healthcare provider or patient/patient representative											
Patient Information* please print	Patient Last Name: Patient First Name:						SS	N:	s	ex	М	F
	Address: Cit				r:			State:	·	ZIP:	:	
	Phone: Day #	Evening #	ng #: Cell #:			l #:	Preferred method of contact: Day					
	DOB: Age: W			eight lb: kg:				Height ft: in:				
	If Patient Is a Minor, Parent/Legal Guard Name: Relation to Patient:											
	Emergency Contact/Relation: Pho			one #: Emo			ail:					
Insurance Information	Section 2: To be completed by healthcare provider or patient/patient representative (Please circle the respondent to indicate who is completing this section.)											
	Does the patient have insurance?  Yes (Please fill out the information below and/or provide copies of insurance card[s], front and back, for primary and secondary insurance)  No (Skip this section)											
	Primary Insurance Company Name:						Phone #:					
ırance	Policy Holder Name:					Policy #:			Group #:			
nsul	Prescription Card Name: Phone #:											
	Policy #:						Group #:					
	Secondary Insurance Company Name:								Phone #:			
	Policy Holder Name:				Policy #:			Group #:				
	Patient's Relationship to Policy Holder: Oself Ochild Ospouse Other											
Additional Team Information(Opti onal)	Section 3: To be completed by healthcare provider or patient/patient representative  Are there any other members of the patient's healthcare team that the patient would like Stealth BioTherapeutics (including its representatives and agents) to discuss care and treatment on FORZINITY with? If so, please include their information below.  By electing to provide this information, I certify that I have permission from the following healthcare team members to											
	disclose their personally identifiable information to, and be contacted by, Stealth BioTherapeutics (including its representatives and agents) for the purpose of supporting the patient's care and treatment on FORZINITY.											
	Care Team Role/Specialty	Name	Email					Pho	ne			



	Section 4: To be completed by healthcare provider									
Prescriber Information	Prescriber Name:		Institution N	Name:						
	NPI:		Medicaid UPIN:		State License #:					
	Address:	City	:	State:	ZIP:					
	Name & Title of Office Contact Person:			Office Contact Person Email:						
	Office Contact Person Phone:			Office Contact Person Fax:						
	PA Office Contact Name:			PA Office Contact Number:						
Prescription	Section 5: To be completed by healthcare provider									
	Prescription for FORZINITY™ (elamipretide) injection									
	The recommended dosage for patients weighing at least 30 kg is 40 mg (0.5 mL) once daily by subcutaneous injection. For patients with eGFR <30 mL per minute and NOT on dialysis the recommended dosage is 20 mg (0.25 mL) subcutaneously once daily.									
escr	Carton contains four 280 mg/3.5 mL (80 mg/mL) single-patient-use vials.									
Ę	SIG: Inject subcutaneously 40	•	•	•	taneously 20 mg (0.25 mL) once daily					
	Dispense:		-Day Supply	Refills:						
	Additional Prescribing Instructions	:								
	Section 6: To be completed by healthcare provider									
>	Primary Diagnosis:			Date of Diagnosis:	Patient Age at Diagnosis:					
essi	ICD-10 code:	her			Therapy Start Date:					
Medical Necessity	Confirmed diagnosis based on (please attach supporting diagnosis documents):  Genetic Testing  Cardiolipin (MLCL:CL) Analysis of Muscle, Platelets, or Cultured Cells  Other									
~	Patient's Allergies:				○ NKDA					
	Current Medications:									
	Section 7: To be completed by healthcare provider									
Prescriber Authorization	I certify I am prescribing FORZINITY™ for this patient for a medically necessary purpose and in the best interest of the named patient.									
	I attest that I have obtained written permission, in the event it is required under applicable federal and/or state law, of my patient (or the patient's legal representative) for the release of my patient's Protected Health Information ("PHI"), as defined by the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), to Stealth BioTherapeutics Inc. or its service providers (collectively "Stealth") as may be necessary for the patient's participation in various assistance pro-grams. I authorize Stealth to convey this prescription on my behalf to the appropriate specialty pharmacy.									
	I understand that I must comply with the state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. I agree that I may be contacted for additional information as needed related to my patient's FORZINITY treatment and/or coordination of care.									
	I understand that I am under no obligation to prescribe FORZINITY or any other Stealth products.									
	Signature (Dispense as Written):			Date:						
	I OR									
	Signature (Substitution Allowed):_		No Stamp Signature		Date:					
	This Patient Enrollment Form is only valid if FAXED to Anovo at 1 (855) 813–2039									



Se	ection 8: To be completed by healthcare provider
	cilled nursing visit as needed to provide patient/patient representative education related to therapy, disease state, dministration (or self-administration) of medication as prescribed.
0	Yes, I would like the specialty pharmacy to coordinate in-home subcutaneous injection training.
	No, I would not like the specialty pharmacy to coordinate in-home subcutaneous injection training.

Signature (Dispense as Written):\_

This Patient Enrollment Form is only valid if FAXED to Anovo at 1 (855) 813–2039

No Stamp Signature



### Section 9: To be completed by patient/patient representative

Patient Consent and Authorization to Share Personal Information: By signing this Authorization, I hereby authorize my healthcare provider, including physicians and their staff, my health plan(s) providing medical care and prescription coverage, and any pharmacies providing FORZINITY™, to disclose my personally identifiable health and insurance information to Mito Assist™ operated by Stealth BioTherapeutics Inc. and their respective partners, affiliates, agents, and Mito Assist service providers (collectively, "Stealth"). This information includes but is not limited to my medical records, prescriptions, insurance coverage information, name, address, telephone number, and any additional information provided in this consent form and any prescription (my "Information"). I authorize Stealth to use my Information and to share it with my healthcare provider, including physicians and their staff, my health plan(s) providing medical care and prescription coverage, and my pharmacies providing FORZINITY.

I authorize Stealth to use and disclose my Information to (i) determine my eligibility for, facilitate my enrollment into, and administer the Mito Assist programs, (ii) ensure quality and safety and improve Stealth's products and services, (iii) analyze the effectiveness of the patient support programs, including data analysis and compliance reviews, (iv) fulfill legal and regulatory requirements, and (v) conduct data analytics and other internal business activities.

Patient Support Services: I authorize Stealth to contact me by mail, email, fax, telephone call, text message (including calls and text messages made with an automatic telephone dialing system or a prerecorded voicemail).\* I authorize Stealth to use my Information to provide support related to FORZINITY, including but not limited to verifying and navigating insurance coverage, providing financial assistance services, providing prescription fulfillment and delivery, administering and evaluating the effectiveness of the patient support program, and offering other support services and disease-related information. I understand that any personnel providing patient support services as part of Mito Assist are not employed by my healthcare provider(s) and may receive compensation from Stealth.

I understand that signing this Authorization is not required to receive medical treatment, health insurance benefits, or other healthcare services, but I will not be able to participate in Mito Assist patient support services without it. I may revoke this Authorization at any time by calling (833) 458–9099. Cancellation will end my consent to further disclosure of my health information to Stealth by my healthcare entities after they are notified of my cancellation but will not affect previous disclosures by them pursuant to this Authorization. Canceling this Authorization will not affect my ability to receive treatment, or my eligibility for health insurance. I have a right to receive a copy of this Authorization. This Authorization expires five (5) years from the date signed unless a shorter period is required by state law. I understand that the specialty pharmacy may receive payment from Stealth for providing patient support services and disclosing associated health information to Stealth pursuant to this Form. I understand that although Stealth has implemented privacy and security controls designed to help protect my Information, once my Information has been disclosed to Stealth, state and federal privacy laws, including the Health Insurance Portability and Affordability Act ( "HIPAA"), may no longer apply and my Information may be subject to redisclosure. Stealth will not sell or trade my personal data to any unrelated third party. More information on Stealth's privacy practices, including specific rights I may have as a resident of certain states, can be found in Stealth's privacy policy at: https://stealthbt.com/privacy-policy/

\*Data rates may apply.

Printed Patient/Legal Representative Name	
Signature of Patient/Patient's Legal Representative	Date
If Legal Representative, Relationship to Patient	

Stealth services and support are subject to change.



	Opt-in for Other Resources: (optional)									
Optional	□ Yes, please, I would like Stealth to contact me regarding other potential topics of interest to me, customer surveys, opportunities to participate in marketing or disease awareness campaigns, or occasionally for market research purposes. I authorize such contact by mail, email, fax, text messaging, telephone (including calls and text messages made with an automatic telephone dialing system or a prerecorded voicemail).* I understand that I am not required to provide this consent as a condition for receiving any Stealth medicine or Mito Assist patient support services.									
	$\ \square$ No, thank you, I would like to opt out of receiving other resources									
	*Data rates may apply.									
	By signing this Authorization, I (the patient or legal representative) hereby authorize the following individuals, in addition to my healthcare provider (physicians and their staff), my health plan(s) providing medical care and prescription coverage, and any pharmacies providing FORZINITY, to disclose my personally identifiable health and insurance information to Mito Assist operated by Stealth BioTherapeutics Inc. and their respective partners, affiliates, agents, and Mito Assist service providers (collectively, "Stealth").									
	Name	Relationship to Patient								
	Signature of Patient/Patient's Legal Representative	Date								

Stealth services and support are subject to change.

Before prescribing Forzinity™, please read the accompanying full Prescribing Information <a href="https://www.accessdata.fda.gov/drugsatfda\_docs/label/2025/215244s000lbl.pdf">https://www.accessdata.fda.gov/drugsatfda\_docs/label/2025/215244s000lbl.pdf</a>

BioTherapeutics Inc.